StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

TG Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was 55.2%. For fiscal 2025 it was 72.6%, against 7.1% the year before. The highest annual figure on record is 72.6% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202572.6%+65.5
FY2024Dec 31, 20247.1%+1.7
FY2023Dec 31, 20235.4%+8041.8
FY2022Dec 31, 2022-8036.3%−2832.3
FY2021Dec 31, 2021-5204.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 20263.2%−16.7
Q1 FY2026Mar 31, 20269.7%+5.5
Q4 FY2025Dec 31, 202512.0%−9.6
Q3 FY2025Sep 30, 2025241.7%+237.1
Q2 FY2025Jun 30, 202520.0%+10.6
Q1 FY2025Mar 31, 20254.2%+21.1
Q4 FY2024Dec 31, 202421.6%+54.4
Q3 FY2024Sep 30, 20244.6%−64.1
Q2 FY2024Jun 30, 20249.4%+305.6
Q1 FY2024Mar 31, 2024-16.9%+485.9
Q4 FY2023Dec 31, 2023-32.8%+98056.0
Q3 FY2023Sep 30, 202368.7%+38173.0
Q2 FY2023Jun 30, 2023-296.2%+6523.7
Q1 FY2023Mar 31, 2023-502.8%+2920.5
Q4 FY2022Dec 31, 2022-98088.8%+6045.5
Q3 FY2022Sep 30, 2022-38104.3%+124869.4
Q2 FY2022Jun 30, 2022-6819.9%+88477.5
Q1 FY2022Mar 31, 2022-3423.3%+89092.5
Q4 FY2019Dec 31, 2019-104134.2%+37602.6
Q3 FY2019Sep 30, 2019-162973.7%−73628.9
Q2 FY2019Jun 30, 2019-95297.4%+20865.8
Q1 FY2019Mar 31, 2019-92515.8%+16771.1
Q4 FY2018Dec 31, 2018-141736.8%−60526.3
Q3 FY2018Sep 30, 2018-89344.7%−6355.3
Q2 FY2018Jun 30, 2018-116163.2%−41550.0
Q1 FY2018Mar 31, 2018-109286.8%–
Q4 FY2017Dec 31, 2017-81210.5%–
Q3 FY2017Sep 30, 2017-82989.5%–
Q2 FY2017Jun 30, 2017-74613.2%–

More TG Therapeutics figures

See a number that looks wrong?